$BNTX News

Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $136

BioNTech (BNTX) Ended A Phase 2 Colorectal Cancer Trial

BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More

BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat

BioNTech drops 10% on mRNA trial failure, highlighting Moderna contrast

BioNTech Stock Dips After BNT122-01 Trial Termination

BioNTech Says It Will Terminate Phase 2 BNT122-01 Trial Of Autogene Cevumeran In ctDNA-Positive Resected Colorectal Cancer After DSMB Identified Numerical Overall Survival Imbalance Between Arms; No New Safety Signals

BioNTech (BNTX) Rallied on Moderna’s Win. Does a Competitor’s Success Validate its Oncology Pipeline?

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

FDA Approves Pfizer And BioNTech's Supplemental Biologics License Application For 2026-2027 COVID-19 Vaccine Formula

BioNTech (BNTX) Is Up 25.2% After First-in-Class Pumitamig Plus B7H3 ADC Lung Data – What's Changed

BioNTech Will Present New Data From Its Development Program in Lung Cancer Treatment at the IASLC 2026 World Conference on Lung Cancer In September; Data Highlights Progress Across Pumitamig (BNT327/BMS986545) and Gotistobart (BNT316/ONC-392), As Well As BioNTech’s mRNA-Based Immunotherapy Approaches

Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight

BioNTech (BNTX) Brings In New CEO As Europe Clears Updated COVID 19 Shot

Citigroup Maintains Buy on BioNTech, Lowers Price Target to $125

Evercore ISI Group Maintains Outperform on BioNTech, Lowers Price Target to $130

BioNTech SE (BNTX) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress Offsets Revenue ...

BioNTech SE (BNTX) Q2 2026 Earnings Call Transcript

BioNTech SE 2026 Q2 - Results - Earnings Call Presentation

BioNTech (NASDAQ:BNTX) Falls After Q2 Revenue Miss and Revised Full-Year Guidance